Singapore markets closed

Straits Times Index
3,313.48
+8.49(+0.26%)
Nikkei
38,787.38
-132.88(-0.34%)
Hang Seng
19,553.61
+177.08(+0.91%)
FTSE 100
8,420.26
-18.39(-0.22%)
Bitcoin USD
66,929.99
+1,477.25(+2.26%)
CMC Crypto 200
1,369.64
-4.20(-0.31%)

SUPN May 2024 36.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.2000

0.0000

(0.00%)

As of 11:09AM EDT. Market open.

GuruFocus.com
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Despite Challenges, Company Shows Promising Growth in Key Areas
Simply Wall St.
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals ( NASDAQ:SUPN ) First Quarter 2024 Results Key Financial Results Revenue: US$143.6m (down 6.6...
GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. A live webcast with presentation slides will